Cardiovascular safety signals with dipeptidyl peptidase-4 inhibitors: A disproportionality analysis among high-risk patients.

Sheriza N BakshMara McAdams-DeMarcoJodi B SegalG Caleb Alexander

Published in: Pharmacoepidemiology and drug safety (2018)

Postmarketing surveillance of DPP-4i through FAERS suggest increased reporting of MACE, supporting the current FDA warning of heart failure risk. This suggests the need for additional longitudinal, observational research into the association of DPP-4i and other MACE.

Keyphrases

heart failure
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
public health
cross sectional
prognostic factors
data analysis